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A central unresolved issue in hepatitis C virus (HCV) infection is how the virus establishes chronic infection. Recent studies suggest that the
liver microenvironment leads to apoptosis of activated T cells, which may be involved in the tolerance to liver allograft. Here, We report that murine
hepatocytes expressing a transgene encoding the HCV structural proteins core, envelope 1 (E1) and envelope 2 (E2) enhance apoptosis of activated
T cells. Unlike normal liver, which appears to selectively remove only activated CD8+ T cells, enhanced apoptosis was seen for both CD4+ and
CD8+ T cells. Enhanced apoptosis of activated T lymphocytes was associated with upregulation of FasL by HCV transgenic hepatocytes and was
specifically inhibited by anti-FasL blocking antibody. Increased apoptosis of activated T cells induced by HCV structural proteins could amplify the
ability of the liver to down-modulate T cell responses, leading to attenuation of anti-viral responses and facilitating viral persistence.
D 2005 Elsevier Inc. All rights reserved.Keywords: HCV; Apoptosis; Immune evasion; Lymphocytes; Hepatocytes; Fas–FasL; Viral persistenceIntroduction
Hepatitis C virus (HCV) infection has become the leading
cause of chronic hepatitis and liver failure in the United States
(Liang et al., 2000). One striking feature of hepatitis C is its
propensity to develop chronic infection in the majority of
infected individuals. A variety of mechanisms for persistence
have been suggested, including quasispecies diversity leading
to immune escape, viral protein interference with host immune
function, and failure to develop an effective immune response.0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.11.017
* Corresponding author. Division of Infectious Disease, Beth Israel Deacon-
ess Hospital, HIM 223a, 330 Brookline Ave., Boston, MA 02115, USA. Fax:
+1 617 975 5235.
E-mail address: mkoziel@bidmc.harvard.edu (M.J. Koziel).
1 Contributed equally.
2 Present address: Digestive Health Specialists, 1703 South Meridian,
Puyallup, WA 98371, USA.In humans and chimpanzees infected by HCV, failure of HCV
clearance appears to correlate with a less vigorous, more
narrowly focused HCV-specific CD4+ and CD8+ T cells
against viral antigens (Cooper et al., 1999; Diepolder et al.,
1995; Lechner et al., 2000a; Missale et al., 1996; Takaki et al.,
2000). Chronic HCV infection is also characterized by an
unusually low frequency of HCV-specific T cells in the liver
and peripheral blood (He et al., 1999), when compared with
other chronic viral infections such as Epstein–Barr virus
(EBV) and human immunodeficiency virus (HIV) infections
(Schmitz et al., 2000; Tan et al., 1999). However, the
mechanism underlying the relatively low frequency of HCV-
specific T cell responses is not clear.
The Fas receptor (Fas, Apo-1/CD95) and its ligand (FasL,
CD95L) are transmembrane proteins of the tumor necrosis
factor family of receptors and ligands. Fas–Fas ligand (FasL)
interaction is one of the main effector mechanisms of cytotoxic
T lymphocytes (Kagi et al., 1994). Engagement of Fas by FasL6) 363 – 372
www.e
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which has a fundamental role in normal biology as well as
pathophysiology in human (Depraetere and Golstein, 1997;
Nagata, 1999). FasL was initially thought to be expressed only
in cells of the lymphoid/myeloid series including T cells and
natural killer cells. Recently, it has been shown that FasL is
expressed by non-lymphoid cells, where it contributes to
immune privilege. In the liver, the Fas–FasL system plays an
important role in regulation of apoptosis of hepatocytes
(Ogasawara et al., 1993) as well as in liver disease, including
liver injury, viral hepatitis, cirrhosis, and HCC (Hahn et al.,
2001; Toubi et al., 2001). Moreover, HCV core plays a role in
the induction of FasL in HepG2 cell line and leads to apoptosis
of the Jurkat T cell line (Ruggieri et al., 2003).
Recent studies have shown that the liver is a unique
immunological organ that can downregulate cellular immune
responses (Belz et al., 1998; Crispe, 1999; Huang et al., 1994).
For example, allogeneic liver transplants are more easily
accepted than other solid organs, and the presence of a liver
allograft can facilitate tolerance to syngeneic organ grafts that
normally would be promptly rejected (Kamada et al., 1981; Rao
et al., 1996). The acceptance of a liver allograft is associated
with apoptosis of host T cells in the liver (Meyer et al., 1999;
Qian et al., 1997), suggesting that the liver can induce tolerance
by inducing activated T cells to undergo apoptosis. In vitro,
both Kupffer cells and hepatocytes can induce activated
alloreactive T cells to undergo apoptosis (He et al., 1999). In
vivo, the liver appears to trap and eliminate activated T cells,
especially CD8+ T cells, via apoptosis during the induction of
peripheral tolerance (Huang et al., 1994; Tagashira et al., 2000;
John and Crispe, 2004; Murray and Crispe, 2004). In fact, it has
been postulated that a physiologic role of the liver is to
terminate immune responses (Crispe et al., 2000). Since the
primary site of replication of HCV is the hepatocyte, we
hypothesized that HCV may enhance the physiologic apoptosis
of activated T cells, thus facilitating viral persistence.Fig. 1. FACS analysis of apoptosis in CD4+ and CD8+ T cells. In this representativ
with FITC-conjugated anti-CD4 or anti-CD8 monoclonal antibody, PE-conjugated a
(Tg+ HC) or non-transgenic (Tg HC) hepatocytes. Shown is a representative FAC
representative experiment is shown.Since HCV only infects human and chimpanzees, and it is
difficult to achieve primary infection of hepatocytes in vitro,
we utilized a murine system of HCV expression in the liver to
model HCV and T cell interactions. We used a line of HCV
transgenic (Tg) mice expressing HCV genotype 1b core, E1
and E2 proteins under the control of the murine albumin
promoter, thus directing expression to hepatocytes and do not
spontaneously develop hepatocellular injury or inflammation
(Kawamura et al., 1997).
In this paper, we report studies of the influence of HCV
structural proteins expressed in these hepatocytes on apo-
ptosis of activated T cells. We demonstrate that hepatocytes
expressing these structural proteins enhance apoptosis of
activated CD4 and CD8 T cells in vitro and in vivo, which
is mediated by increased expression of Fas ligand in Tg
hepatocytes.
Results
Expression of HCV core/E1/E2 induces apoptosis of activated
T cells
To study the influence of hepatocytes expressing HCV
core, E1 and E2 proteins on cell death of activated T cells,
we co-cultured Tg+ hepatocytes with sex and MHC-
matched, activated T cells that were isolated from non-Tg
littermates. Hepatocytes isolated from non-Tg littermates
were used as controls. Apoptosis of activated T cells was
studied by three-color FACS analysis. To this end,
lymphocytes that were recovered from co-culture with
hepatocytes were stained with FITC-conjugated anti-mouse
CD4 or CD8 antibody and then with PE-conjugated
Annexin V and propidium iodide (PI). In the representative
experiment shown in Fig. 1, co-culture of Con-A activated
CD4+ T cells with HCV Tg+ hepatocytes increased early
apoptotic events from 7.5% to 12.5% (AV+/PI, right lowere experiment, FACS analysis was performed on activated T cells after staining
nnexin V and propidium iodide (PI), 15 h after co-culture with HCV transgenic
S profiles after gating on CD4+ (upper panel) or CD8+ (lower panel) T cells. A
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increased from 6.8% to 10.4%. We chose to analyze
Annexin V+/PI cells as a more specific marker of early
apoptosis in lymphocytes than all AV+ cells (Eray et al.,
2001; McCloskey et al., 1998). However, note that in
this representative example, if we compare total AV+,
there is 34% AV+ CD4+ cells in HCV Tg+ mice
compared to 13.5% in Tg controls; for CD8+ T cells,
there is 33.1% AV+ cells in HCV Tg+ compared to
23.5% in Tg controls.
As shown in Fig. 2, multiple experiments confirm that
apoptosis of both CD4+ and CD8+ T cells was significantly
increased after co-culture with HCV Tg+ hepatocytes for 4
and 15 h, as compared with T cells co-cultured with non-Tg
hepatocytes. After only 4 h of co-culture, there was a
statistically significant difference in early apoptosis that was
apparent between T cells co-cultured with HCV Tg hepato-
cytes and those co-cultured with non-Tg hepatocytes (Fig. 2).
The percentage of annexin V+/PI cells was increased from a
median value of 9.5% in those CD4+ T cells cultured with
the non-Tg hepatocytes to a median of 14.6% (Fig. 2A) when
cultured with Tg hepatocytes. For CD8+ T cells, the median
value of cells in early apoptosis was 6.8% after co-culture
with non-Tg hepatocytes and 12.5% after co-culture with
HCV Tg hepatocytes. Apoptosis was also significantly
increased in both activated CD4+ and CD8+ T cells 15
h after co-culture with transgenic hepatocytes expressing the
HCV structural proteins. The median percentage of annexin
V+/PI cells was increased from a median value of 14% inFig. 2. Increased apoptosis of activated CD4+ and CD8+ T cells after co-culture with
activated T cells was studied by 3-color FACS analysis, 4 or 15 h after co-culture w
(A) T cells in the early phase of apoptosis (annexin V-positive, PI-negative) are show
(HCV Tg+) compared to non-transgenic (HCV Tg) hepatocytes was seen at both 4
of five to eight independent experiments were analyzed by Mann–Whitney U test. (B
hepatocytes. In this example, data for Tg hepatocytes were normalized to the app
significant at 4 and 15 h. (C) All annexin V+ cells, showing increased apoptosis of b
(D) Relative increase in all AV+ cells.those CD4+ T cells cultured with the non-Tg hepatocytes to a
median of 21% (Fig. 2A) when cultured with Tg hepatocytes.
For CD8+ T cells, the median value of cells in early
apoptosis was 15.6% after co-culture with non-Tg hepato-
cytes and 21% after co-culture with HCV Tg hepatocytes. As
shown in Fig. 2B, if the relative fold increase in early
apoptotic (AV+/PI) cells is compared, there is a statistically
significant increase for both time points for both CD4+ and
CD8+ cells.
When all annexin V+ cells were analyzed (Fig. 2C), the
differences remained statistically significant, with the excep-
tion of the difference between CD8+ cells at 4 h. As expected,
the absolute values for all AV+ increased over time. For
example, in the case of CD4+ T cells, the median value of AV+
cells after 15 h of co-culture was 17.3% after co-culture with
non-Tg hepatocytes and 28.5% after co-culture with HCV Tg
hepatocytes. For CD8+ T cells, the median value of 30% of
cells after co-culture for 15 h increased to 37% after co-culture
with HCV Tg hepatocytes. Similarly, there is an increase in the
relative degree of apoptosis if all AV+ cells are measured, with
the exception of CD8+ cells at the early time point (Fig. 2D).
The data suggest that CD8+ T cells at 4 h are primarily still in
the early phases of apoptosis and have not progressed to later
stages. Non-activated T cells had very low levels of apoptosis,
and there is no difference between Tg+ and Tg for non-
activated cells (data not shown). Taken together, the data
suggest that the expression of HCV structural proteins in
hepatocytes increases the apoptosis of activated CD4+ and
CD8+ T cells.transgenic hepatocytes expressing HCV core, E1 and E2 proteins. Apoptosis of
ith HCV transgenic (Tg+, stippled) or non-transgenic (Tg, open) hepatocytes.
n. Increased apoptosis of activated T cells after co-culture with HCV transgenic
and 15 h and was seen for both CD4+ (circles) and CD8+ (squares) cells. Data
) The relative increase of early apoptotic cells increases after co-culture with Tg
ropriate Tg control. Results for both CD4+ and CD8+ remain statistically
oth CD4+ and CD8+ T cells at 15 h, and an increase in CD4+ AV+ cells at 4 h.
K. Iken et al. / Virology 346 (2006) 363–372366Increased apoptosis of activated T cells is associated with
upregulation of Fas ligand expression on HCV transgenic
hepatocytes
Activated T cells may be induced to undergo apoptosis by a
variety of death-inducing molecules, including FasL (also
known as CD95 ligand), TNFa (Crispe, 1999), galectin-1
(Baum et al., 1995), and TNFa related apoptosis inducing
ligand (TRAIL, also known as Apo-2 ligand) (Jeremias et al.,
1998). To study whether any of these death-inducing
molecules is responsible for increased apoptosis of activated
T cells induced by hepatocytes expressing HCV proteins, we
studied and compared the expression of these molecules
between HCV Tg+ and non-Tg hepatocytes. We performed
Western blotting analysis to study the expression of FasL,
TRAIL, and galectin-1 using specific antibodies against these
molecules. The level of FasL expression was increased in
HCV Tg hepatocytes relative to their non-Tg counterparts
(Fig. 3A). The findings were similar for total RNA using RT-
PCR (Fig. 3B), as well as analysis of cell surface FASL
expression using flow cytometry (Fig. 3C). To measure the
concentration of TNFa in the supernatants of co-culture of
hepatocytes and activated T cells, we used ELISA. No
statistically significant difference was observed between
HCV Tg+ hepatocytes and non-Tg hepatocytes at either 4 orFig. 3. Increased expression of Fas ligand in HCV transgenic hepatocytes
expressing structural proteins. (A) Cell lysates (200 Ag) were subjected to
Western blot analysis using specific polyclonal rabbit anti-mouse Fas ligand
antibodies. The level of cellular murine beta actin is shown as an internal
control for comparison. One representative experiment is shown. (B) Induction
of mRNA for FasL by HCV structural proteins. Whole-liver tissue from Tg
and Tg+ mice was harvested; RNA was extracted and analyzed by reverse
transcription PCR for FasL transcripts. Results for GAPDH mRNA are shown
as controls. Results are a representative experiment of 3 individual experiments.
(C) Differences in surface expression of FasL analyzed by flow cytometry.
Freshly isolated HC were stained with 0.5 Ag/ml FasL. Tg+ HC (thick line) had
increased expression of FasL compared to Tg HC (dashed line), which had
only minimal increase compared to the isotype control (thin dashed line). One
representative experiment of three is shown. (D) Activated lymphocytes show
no difference in surface FasL expression after co-culture with either Tg or
Tg+ hepatocytes.15 h of co-culture (data not shown). Expression of either
TRAIL or galectin-1 was not observed in Tg or non-Tg
hepatocytes (data not shown). After co-culture with HCV-
expressing hepatocytes, there was no change in FasL
expression on lymphocytes (Fig. 3D).
Enhanced apoptosis of activated T cells induced by HCV
transgenic hepatocytes is Fas–FasL dependent
To determine whether Fas–FasL interaction is indeed
responsible for enhanced apoptosis of activated T cells
induced by hepatocytes expressing HCV proteins, we per-
formed blocking experiments using polyclonal rabbit anti-
mouse FasL antibodies. Purified normal rabbit IgG was used
as a control. As shown in Fig. 4, the addition of 10 Ag/ml anti-
FasL antibodies decreased apoptosis of activated CD4+ and
CD8+ T cells induced by Tg+ hepatocytes expressing HCV
structural proteins compared to cells incubated with Tg
hepatocytes and either media or the isotype control antibody.
Similar findings were observed for alloreactive T cells (data
not shown). It is important to note that anti-FasL antibodies
had no effect on apoptosis of activated CD4+ or CD8+ T cells
induced by non-transgenic hepatocytes (Fig. 4), suggesting
that basal apoptosis of activated T cells induced by hepato-
cytes in the absence of HCV is mediated by death-induced
molecule(s) other than those mentioned above. These consis-
tent with a previous report that Fas-deficient mice do not have
different kinetics of T cell apoptosis within the liver (Mehal
and Crispe, 1998), so that physiologic depletion of activated T
cells within the normal liver is not dependent on Fas–FasL
interaction.
Apoptosis of activated T cells occurs in vivo
In order to confirm that apoptosis of activated T cells is
accelerated in vivo in HCV transgene positive (Tg+) compared
to non-Tg mice, we performed adoptive transfer of concanav-
alin A activated T cells into Tg+ mice and their non-Tg
littermates (Fig. 5). Splenocytes from non-Tg littermates were
activated with conA and labeled with supravital dye CFSE in
order to track them in vivo. These labeled cells were infused
into the portal circulation of HCV Tg+ and non-Tg littermates.
Sixteen hours after infusion, intrahepatic lymphocytes were
harvested and analyzed for the degree of apoptosis among
CFSE+ cells. As shown in Fig. 5A, the degree of apoptosis was
significantly higher among the intrahepatic lymphocytes of
HCV Tg+ animals. Resting T cells from HCV non-Tg mice
were also CFSE labeled and adoptively transferred into HCV
Tg+ and non-Tg mice. CFSE cells were readily detected in the
spleen, with few cells present in the liver; there was no
difference in apoptosis or cell number between HCV Tg+ and
non-Tg mice (data not shown). This observation is consistent
with prior published data, suggesting that there is no apoptosis
within the liver of resting T cells (Huang et al., 1994).
Similarly, rare CFSE+ cells were detected within splenocytes
(<0.5% of cells), and there was no difference in the degree of
apoptosis of CFSE+ cells (data not shown). In order to confirm
Fig. 4. HCV induces apoptosis through Fas–FasL cascade. (A) Anti-Fas ligand antibodies inhibit enhanced apoptosis of activated CD4+ and CD8+ T cells induced
by transgenic hepatocytes expressing HCV core, E1 and E2 proteins. Apoptosis of activated T cells was studied by 3-color FACS analysis 15 h after co-culture with
HCV transgenic hepatocytes (Tg+ HC), in the presence of 10 Ag/ml rabbit anti-mouse Fas ligand polyclonal antibodies (Ab) or purified rabbit IgG (IgG) as an
isotype control or media (Med). Results are based on binding of annexin Vafter gating on viable CD4+ and CD8+ cells. Shown are means and standard deviations of
5 experiments.
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antibody that blocks Fas–FasL interaction. This significantly
reduced the apoptosis of CFSE+ cells following adoptive
transfer in HCV Tg+ mice (Fig. 5B), whereas there was no
significant difference in apoptosis following adoptive transfer
into non-Tg mice.
To examine whether the increased apoptosis of activated T
lymphocytes by HCV Tg+ hepatocytes occurred via the
conventional Fas-mediated pathway, we examined the activa-
tion of and necessity for specific caspases involvement in this
pathway. Caspase-3 is a downstream, effector caspase that is
activated in response to ligand-mediated Fas signaling, among
others. After co-culture with either Tg+ or non-Tg hepatocytes,
lymphocytes were harvested for measurement of caspase-3
activity by detection of the cleavage of colorimetric substrate
of this caspase. As shown in Fig. 6, activation of caspase-3 in
activated lymphocytes was significantly increased after 15 h ofFig. 5. Increased apoptosis of activated T cells after adoptive transfer into HCV Tg m
text. The degree of apoptosis in CFSE+ cells by AV staining was determined 16 h
independent experiments with 2–3 mice in each group are shown are shown. (B) HC
Oncogene Research) or the isotype control. Data (median (IQR)) for 3 HCV Tg+
experiments. Statistical significance by Mann–Whitney.co-culture with Tg+ hepatocytes compared to non-Tg hepato-
cytes. These data demonstrate that expression of HCV proteins
by hepatocytes mediates apoptotic signaling of activated T cells
that is dependent on Fas–FasL interaction.
Discussion
We have shown here that the expression of HCV core, E1
and E2 proteins in HCV Tg hepatocytes induces enhanced
apoptosis of activated CD4+ and CD8+ T cells in vitro and in
vivo. In our studies, there was an upregulation in FasL
expression in the liver, consistent with published observations
increased expression of both Fas and FasL mRNA in the liver
in humans with chronic hepatitis C (Galle et al., 1995;
Hiramatsu et al., 1994; Mita et al., 1994; Tagashira et al.,
2000) and in hepatoma cells transfected with HCV core protein
(Ruggieri et al., 2003). Our data therefore suggest that theice. Cells were activated with conA and given via intraportal injection as in the
following adoptive transfer. Median values and intraquartile ranges (IQR) of 3
V Tg+ or non-Tg mice were treated with 20 Ag/mouse of anti-FasL Ab (Ab-1,
and 3 non-Tg mice (difference not significant) in each of two independent
Fig. 6. Caspase-3 activity of activated lymphocytes in HCV Tg+ and non-HCV
Tg mice. Caspase-3 activity was measured in lysates from cells by release of
pNA from peptide substrates as described in Materials and methods. Results
represent the average of three independent experiments.
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specific T cells in chronic HCV infection are related to
increased apoptosis of activated, virus-specific T cells. Al-
though we used polyclonally activated, non-HCV-specific T
cells in our experiments, these findings need to be examined in
future studies with HCV-specific cells.
We have shown here that both CD4+ and CD8+ T cells
were induced by hepatocytes to undergo apoptosis in vitro.
This differs from previous in vivo studies in non-Tg mice,
which have shown that trapping and elimination of activated
T cells are limited to activated CD8+ T cells and not CD4+ T
cells (Belz et al., 1998; Crispe, 1999; Crispe et al., 2000; Emi
et al., 1999; Huang et al., 1994). Following activation, CD8+
T cells appear in the periphery and spleen initially. As these
CD8+ T cells disappear from the lymph nodes and spleen,
they accumulate in the liver, where they undergo apoptosis.
This apoptosis of activated T cells has been shown in two
different systems, namely autoreactive cells in H-2k transgenic
mice (Bertolino et al., 1995) and T cells isolated from TCR
Tg mice injected with peptide (Mehal et al., 1999; Wack et
al., 1997). This is specific for activated cells, as activated but
not resting cells are selectively retained by the normal liver
(Mehal et al., 1999). In a more physiologic model, during
influenza infection in the mouse, where the infection is
limited to the respiratory tract, the resolution phase of the
infection is associated with accumulation of apoptotic, virus-
specific CD8+ T cells in the liver, not in the lymph node or
lung (Belz et al., 1998). Deletion of activated CD8+ T cells
has been postulated to play a significant role not only in T
cell homeostasis but also in the relative tolerance of liver
allografts (Qian et al., 1997). For example, in a B10 (H-2b) to
C3H (H-2k) transplant model, manipulation of the model to
decrease apoptosis of infiltrating T cells in the liver led to an
increase in rejection. The mechanism whereby the normal
liver selectively retains activated CD8+ T cells is not entirely
understood, but in normal liver tissue, this does not appear to
be dependent on Fas–FasL interactions, as Fas-deficient mice
do not have different kinetics of T cell apoptosis within the
liver (Mehal and Crispe, 1998).
Resolution of acute HCV appears to be dependent on the
coordinated activity of both CD4+ and CD8+ T lymphocytes
in acutely infected chimpanzees and man, with chronic HCV
infection marked by the failure to develop and sustain aneffective T lymphocyte response (Diepolder et al., 1996;
Grakoui et al., 2003; Missale et al., 1996; Shoukry et al.,
2003; Takaki et al., 2000). Thus, the dominant cause of viral
persistence might be the development of a weak immune
response to viral antigens with a corresponding inability to
eradicate HCV-infected cells. Moreover, in subjects who
develop chronic infection the frequency of HCV-specific
CTL displaying activation markers declines rapidly during
the initial phase of the infection despite ongoing viremia,
suggesting an active termination of the immune response
(Lechner et al., 2000a). The weakness of virus-specific T cell
responses is reflected in the unusually low frequency of
HCV-specific T cells in patients with chronic HCV infection,
as compared with other viral infections. For example, in
chronic HIV infection and in latent EBV infection in
humans, up to 10% of the T cells in peripheral blood are
virus specific (Ogg et al., 1998, 1999; Tan et al., 1999;
Tussey et al., 2000). In contrast, the frequency of HCV-
specific CD8+ T cells detected by the same techniques is
much lower in chronic HCV infection. In one study, He et
al. showed that the frequency of HCV-specific CD8+ T cells
was <0.01% in peripheral blood in more than half of the
patients, as revealed by staining with two MHC/HCV
peptide tetramers that detect CD8+ T cells specific for two
epitopes in the NS3 protein (He et al., 1999). Although
HCV-specific CD8+ T cells are relatively enriched in the
liver compared with peripheral blood, they still only account
for 1–2% of intrahepatic CD8+ T cells. Similar results were
reported by Lechner et al., who found that in more than half
of the patients with chronic HCV infection, virus-specific
CD8+ T cells were not detectable in the peripheral blood by
staining with MHC/HCV peptide tetramers (Lechner et al.,
2000b). In the remaining patients where HCV-specific cells
could be detected, the average percentage of HCV-specific
CD8+ T cells was only 0.07% in peripheral blood
lymphocytes. Possible mechanisms of this relatively low
frequency of HCV-specific T cells responses include a failure
to generate virus-specific T cell response due to impaired
antigen presentation (Bain et al., 2001; Kanto et al., 1999).
Here, we suggest that CD95L-positive hepatocytes increase
apoptosis of activated effector T cells, which might thereby
promote chronic infection.
There have been several conflicting reports on the role of
HCV proteins in immunosuppression, with evidence both for
(Large et al., 1999) and against (Liu et al., 2002; Sun et al.,
2001) the role of HCV structural proteins in failure to clear
other viral infections. We do not believe that the apoptosis of
activated T cells observed in our model necessarily must result
in an absolute failure of virus-specific immune responses.
There was not an absolute elimination of either CD4+ or CD8+
T cells, consistent with observations that these mice do not
have abnormalities in CD4+ or CD8+ cells compared to
littermate controls (data not shown). However, multiple
observations of increased apoptosis of T cells in patients with
chronic HCV infection in both the periphery (Emi et al., 1999;
Taya et al., 2000; Toubi et al., 2001) and liver (Nuti et al.,
1998) are consistent with our hypothesis and support the
K. Iken et al. / Virology 346 (2006) 363–372 369physiologic relevance of these studies. Although HCV patients
are not considered to be immunosuppressed, recent studies
have shown defects in the memory T lymphocyte response
against heterologous viruses (Lucas et al., 2004), an observa-
tion which could be related to increased apoptosis of T
lymphocytes.
In summary, our results have shown that the HCV structural
proteins increase the expression of FasL in hepatocytes and
enhance the ability of hepatocytes to induce apoptosis of
activated T cells. We propose that this apoptosis upon exposure
to HCV-infected hepatocytes in the liver is one mechanism that
contributes to the ineffective immune response against this
virus. Increased apoptosis of activated T cells induced by
hepatocytes expressing HCV proteins may amplify the ability
of the liver to down modulate T cell responses, contributing to
HCV persistence.
Materials and methods
Mice
The line of HCV transgenic (Tg+) mice carrying a
transgene that encodes the core, E1 and E2 proteins of type
1b HCV has been described previously (Kawamura et al.,
1997). The expression of the transgene is under the control of
a liver-specific murine albumin promoter. This line of HCV
transgenic mice was originally created in FVB background and
bred to BALB/c mice to generate (FVB  BALB/c) F1 mice
(H-2q/d). Transgenic mice were typed by PCR as previously
described (Kawamura et al., 1997). Age- and sex-matched
littermates negative for expression of HCV (Tg) were used
as a control.
Isolation and culture of murine hepatocytes
Murine hepatocytes were isolated by in situ perfusion via
the portal vein with collagenase IV solution (Gibco BRL),
according to standard techniques as described (Klaunig et al.,
1981). Cells were washed three times in RPMI supplemented
with 10% FCS, 1% penicillin and streptomycin, and 2 mM
glutamine before being plated into Primaria 24- or 6-well
plates in William’s medium supplemented with insulin (10
Ag/ml), EGF (50 ng/ml) and glucagon (10 Ag/ml), as
described (Enat et al., 1984). Non-adherent cells, including
contaminating lymphocytes, were removed by washing 4
h after plating, and the hepatocytes were then cultured for 24
to 48 h.
Activation of T cells
Splenic T cells were isolated from non-transgenic controls,
and cultured in vitro for 24 h in the presence of 5 Ag/ml
Concanavalin A (Con A) in RPMI medium supplemented with
10% FCS, penicillin (100 U/ml), streptomycin (100 Ag/ml),
HEPES buffer, and l-glutamine (2 mM). Gradient centrifuga-
tion was performed over Ficoll-Hypaque immediately before
use to maximize the viability of activated T cells used in co-culture. Freshly isolated ex-vivo splenic T cells were used as
resting T cell controls. In addition, cells were also activated by
co-culture of splenic T cells from C57/B6 mice (H-2b) with
non-transgenic splenocytes (H-2q/d) for 48–72 h.
Co-culture of activated T cells and primary cultured
hepatocytes
Four million activated, unfractionated T cells were co-
cultured with adherent HCV transgenic or non-transgenic
hepatocytes. After incubation for indicated periods of time,
lymphocytes were harvested by pipetting. Hepatocytes remain
adherent after pipetting. After one wash in PBS, viable
lymphocytes were counted using a hemacytometer. Trypan
blue was used to exclude non-viable cells. In some experi-
ments, co-cultures were performed by adding antibody, 10 Ag/
ml anti-FasL (Ab-1, Oncogene Research Products, Boston,
MA), or the isotype control antibody, and then apoptosis was
measured in CD4+ and CD8+ T cells.
Staining of apoptotic cells by annexin V
0.1–0.5  106 recovered lymphocytes were stained for
30 min in U-bottomed 96 plates with FITC-conjugated anti-
CD4 (BD Pharmingen, San Diego, CA) or anti-CD8
monoclonal antibody (BD Pharmingen, San Diego, CA),
dissolved in PBS containing 1% FCS and 0.1% sodium
azide. Thirty minutes before FACS analysis, cells were then
stained with PE-conjugated annexin V (BD Pharmingen, San
Diego, CA) and propidium iodide (PI; BD Pharmingen, San
Diego, CA), as suggested by the manufacturer. During FACS
analysis, a live acquisition gate was placed on lymphocytes
based on FSC/SSC profile. Side and forward angle light
scattering was used to electronically gate the cells of choice
and to exclude debris. Ten thousand events within the gate
region were collected for each sample. Rare contaminating
hepatocytes were excluded on the basis of FSC/SSC. The
percentages of CD4+ and CD8+ T cells and the percentages
of CD4+ and CD8+ T cells that were annexin V and/or PI
positive were measured by FACScan using CellQuest
software (BD, San Jose, CA). The absolute numbers of
viable CD4+ and CD8+ T cells were calculated by
multiplying the total number of viable lymphocytes recov-
ered from individual co-cultures with the percentages of
CD4+ and CD8+ T cells, respectively.
Adoptive transfer and in vivo activation
Splenocytes from non-Tg littermates were activated with
conA as above. Forty-eight hours later, five to ten million
CFSE-labeled cells were injected via the portal circulation
into HCV Tg mice as described (Huang et al., 1994). Non-
Tg littermates were used as controls. Sixteen hours after
injection, the animals were sacrificed, and liver and spleen
lymphocytes were harvested. The degree of apoptosis of
CFSE labeled cells was analyzed as described above. In
some experiments, HCV Tg+ or non-Tg mice were treated
K. Iken et al. / Virology 346 (2006) 363–372370with 20 Ag/mouse of anti-FasL Ab (Ab-1, Oncogene
Research) or the appropriate isotype control prior to adoptive
transfer of cells.
Western blotting analysis
200 Ag of cell lysates of freshly isolated transgenic and non-
transgenic hepatocytes were electrophoresed in 10% SDS-
PAGE and transferred to nitrocellulose membrane. Immunode-
tection was performed using the enhanced chemiluminescence
technique (NEN Life Science Products, Boston, MA). The
following specific antibodies were used in the study: polyclonal
rabbit anti-mouse Fas ligand antibodies (Ab-1, Oncogene
Research Products, Boston, MA), polyclonal anti-mouse h-
Actin, polyclonal rabbit anti-serum to galectin-1 (gift of Dr.
Linda Baum; University of California, Los Angeles, CA), and a
monoclonal antibody against TRAIL (clone N2B2; gift of Dr.
Hideo Yagita, Juntendo University, Japan). Mouse beta actin
(clone C-11, Santa Cruz) was used as a control, and expression
of FasL was normalized to beta actin. Densitometry was
performed using the NIH Image software downloaded from
the NIH web site.
RNA isolation and RT-PCR
Liver tissue from Tg+ or non-Tg littermates was harvested,
and total RNA was isolated using the TriZol reagent (Invitro-
gen, Inc. Carlsbad, California) according to the manufacturer’s
instructions. For RT-PCR, 2 Ag of total RNAwas treated for 15
min at room temperature with 2 U of amplification grade
DNase I (Invitrogen, Inc. Carlsbad, California) to remove the
genomic DNA. The cDNA was generated from 2 Ag of total
RNA using Ready-To-Go First-Strand Beads (Amersham
Biosciences, Piscataway, NJ). RT-PCR amplifications of cDNA
were carried out using the PTC-100 Thermal Controller (MJ
Research, Inc. Waltham, MA) as follows: 5 min at 94 -C, 35
cycles of 1 min at 94 -C, 1 min at 55 -C, and 2 min at 72 -C
extension, followed by 10 min at 72 -C. The PCR products
were analyzed on 1.5% agarose gel, stained with ethidium
bromide, and visualized with UV light. The sense primer for
FasL was 5V-TCATCTTGGGCTCCTCCAGGGTCAG-3V, and
the antisense primer was 5V-GGCTTTGGTTGGTGAACT-
CACGGAG-3V (nucleotides 185–483), which gave a 298-bp
PCR product.
Flow cytometric analysis of FasL expression
For analysis of surface expression of FasL on hepatocytes, a
total of 1  106 freshly isolated hepatocytes were stained with
an optimal dilution of PE-anti-mouse Fas Ligand antibody
(MFL3 clone, Pharmingen, San Diego, CA). After several
washes with PBS, hepatocytes were incubated in blocking
solution (PBS containing 5% normal mouse serum) at 4 -C for
30 min and then with PE-conjugated anti-FasL at 4 -C for 30
min. Fluorochrome-conjugated isotype-matched Abs were used
as controls for non-specific binding. In all experiments, cells
were taken from either Tg+ or non-Tg littermates as controls.Data were acquired on a FACScan flow cytometer. Data were
analyzed using CellQuest software (BD Biosciences, San Jose,
CA). Similar experiments were performed to analyze the
expression of FasL and Fas on lymphocytes. In these
experiments, lymphocytes were activated as above, then co-
cultured with either Tg+ or non-Tg hepatocytes. FasL and Fas
expressions were measured as above.
Caspase-3 activity
Following co-culture with either Tg+ or non-Tg hepatocytes,
lymphocytes were collected, purified using Ficoll-Hypaque
centrifugation, and the pellet was lysed by addition of lysis
buffer. The lysates of 2  106 cells were incubated on ice for 10
min and centrifuged at 10,000  g for 1 min. The supernatant
was collected and used as cell lysate. The activity of caspase-3
was measured using caspase-3 colorimetric Assay kit (R&D
Systems, Inc. Minneapolis, MN) according to the manufacturer.
Briefly, lysates were incubated with caspase-3 colorimetric
substrate (DEVD-pNA) for 2 h at 37 -C in a 96-well flat bottom
microplate. Upon cleavage of the substrate, the liberated
chromophore pNA is spectrophotometrically detected. The
pNA light emission was quantified using a microtiter plate
reader at 405 nm. The level of caspase-3 enzymatic activity in
the cell lysate is directly proportional to the color reaction.
ELISA
The concentration of tumor necrosis factor a (TNF a) was
measured using a TNF a ELISA kit (Endogen, Woburn, MA)
according to manufacturer’s specifications.
Statistical analysis
Statistical analysis was performed using the StatView
software (SAS Institute Inc., Cary, NC). Analysis was
performed using student t test for parametric data and
Mann–Whitney test for non-parametric, as appropriate, and
Kruskal–Wallis for comparison of multiple groups.
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